Martine A. Rothblatt Sells 1,256 Shares of United Therapeutics Corporation (UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,256 shares of the business’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $122.98, for a total transaction of $154,462.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Corporation (NASDAQ:UTHR) opened at 123.87 on Friday. The company’s 50-day moving average price is $124.46 and its 200 day moving average price is $126.92. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89. The company has a market capitalization of $5.38 billion, a PE ratio of 14.37 and a beta of 1.49.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million during the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. United Therapeutics Corporation’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.42 EPS. On average, equities research analysts anticipate that United Therapeutics Corporation will post $10.60 EPS for the current year.

WARNING: “Martine A. Rothblatt Sells 1,256 Shares of United Therapeutics Corporation (UTHR) Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/10/08/martine-a-rothblatt-sells-1256-shares-of-united-therapeutics-corporation-uthr-stock.html.

Several research firms recently commented on UTHR. TheStreet lowered shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a research report on Friday, September 29th. BidaskClub lowered shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. ValuEngine lowered shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Finally, Zacks Investment Research lowered shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Six analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $132.09.

A number of institutional investors have recently bought and sold shares of UTHR. BlackRock Inc. boosted its stake in United Therapeutics Corporation by 4,222.8% in the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock worth $641,969,000 after purchasing an additional 4,632,287 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of United Therapeutics Corporation by 144.0% during the second quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock worth $94,785,000 after acquiring an additional 431,210 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of United Therapeutics Corporation by 308.6% during the second quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock worth $64,930,000 after acquiring an additional 378,002 shares during the last quarter. AQR Capital Management LLC raised its position in shares of United Therapeutics Corporation by 27.8% during the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock worth $235,068,000 after acquiring an additional 377,395 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of United Therapeutics Corporation by 65.5% during the second quarter. Renaissance Technologies LLC now owns 837,600 shares of the biotechnology company’s stock worth $108,662,000 after acquiring an additional 331,400 shares during the last quarter.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply